|
|
|
|
|
|
|
|
|
|
In this discussion of formulation, dose, and device alignment, expert panelists Rubi Burlage, Dominick DeGrazio, and John Higgins will join host Tom von Gunden in a discussion of key considerations that should guide your weighing of delivery options. Register for free thanks to BD Pharmaceutical Systems.
|
|
|
|
|
|
|
|
By Drug Delivery Leader: Sit and Deliver
|
In this episode of Sit and Deliver, host Tom von Gunden talks with OmniSpirant Therapeutics CEO Gerry McCauley about leveraging stem cell-derived exosomes for platform delivery of gene therapies targeting cancers, respiratory diseases, and other indications. They consider patient safety along the way of transforming life-threatening diseases into manageable, treatable conditions.
|
|
|
|
|
|
4 Opportunities For Advancing Drug Delivery
|
|
By Fran DeGrazio, senior industry & technical advisor, Drug Delivery Leader
|
In this article, Fran DeGrazio identifies four prime opportunities for drug delivery developers to move the dial of innovation into 2026 and beyond. These avenues for advancement include diagnostics, patient tolerability, microdosing, and analytical methodologies.
|
|
|
|
|
|
|
|
De-Risking FDA ANDA Submissions With An Autoinjector Platform
|
|
Infographic | BD Medical - Pharmaceutical Systems
|
Discover an autoinjector platform that supports ANDA pathways with demonstrated usability and design alignment to help development teams reduce risk and move confidently toward regulatory submission.
|
|
|
|
|
|
|
|
|
|
|
|
|
The 4th Nasal Formulation & Delivery Summit is uniting formulation, delivery, and product development leaders to advance the development of safe, effective, and commercially viable intranasal therapies. Join 70+ experts from Eli Lilly, Bayer, Neurelis, Virpax Pharmaceuticals, Belhaven Biopharma, and more to explore real-world preclinical and clinical data, compare liquid and powder nasal approaches, and align on best practices for systemic and nose-to-brain delivery.
|
|
|
|
|
|
|
|
|
.png){kind=logo}
